Assistant Professor of Medicine, SUNY Buffalo
Internal Medicine
Dr. Marwan Fakih, MD
|
|
Give Review
Marwan Fakih practices Internal Medicine. He went to medical school at Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine He received awards:"America's Top Doctors", "Top Doctors:LA Area" and "America's Top Doctors for Cancer". Marwan Fakih, MD is also published. He has 100 publications published. The lastest publication: "Specific binding of Haemophilus influenzae to minor gangliosides of human respiratory epithelial cells.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic coloRectal cancer: A randomized phase 1b/2 trial.
- Localized Colon Cancer, Version 3.2013.
- Serum Vitamin D Metabolites in ColoRectal Cancer Patients Receiving Cholecalciferol Supplementation: Correlation with Polymorphisms in the Vitamin D Genes.
- Metastatic Colon Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines.
- A Prospective Clinical Trial of Cholecalciferol 2000 IU/day in ColoRectal Cancer Patients: Evidence of a Chemotherapy-response Interaction.
- Intensive Radiographic and Biomarker Surveillance in Stage II and III ColoRectal Cancer.
- Single-agent paclitaxel in advanced Anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
- Methyl selenocysteine: single-dose pharmacokinetics in men.
- A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory coloRectal cancer.
- Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced ColoRectal Cancer.
- First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine Tumors of colon and rectum (MCRC NET): review of 8 cases.
- Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate Cancer patients.
- Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic coloRectal cancer.
- Serological immune responses to influenza vaccine in patients with coloRectal cancer.
- 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine Analog, capecitabine.
- Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic coloRectal cancer.
- Renal atrophy Secondary to chemoradiotherapy of abdominal malignancies.
- Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refrac...
- A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory soli...
- Adverse events associated with anti-EGFR therapies for the treatment of metastatic coloRectal cancer.
- Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic coloRectal cancer.
- Positron emission tomography as predictor of Rectal cancer response during or following neoadjuvant chemoradiation.
- Quantitative methodology using CT for predicting survival in patients with metastatic coloRectal carcinoma: a pilot study.
- Management of Anal cancer in 2010. Part 2: current treatment standards and future directions.
- Management of Anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
- Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen.
- A case of curative-intent hepatectomy for colon Cancer metastatic to the scapula and liver.
- NCCN clinical practice guidelines in oncology. Anal carcinoma.
- A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid Tumors.
- Vitamin D deficiency and insufficiency among patients with prostate Cancer.
- A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic coloRectal cancer.
- NCCN Clinical Practice Guidelines in Oncology: Rectal cancer.
- NCCN Clinical Practice Guidelines in Oncology: colon Cancer.
- A case of 5-fluorouracil-induced acute psychosis.
- A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorect...
- Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
- Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III coloRectal cancer.
- Spontaneous regression of coloRectal cancer metastatic to retroperitoneal lymph nodes.
- Chemotherapy is linked to severe vitamin D deficiency in patients with coloRectal cancer.
- Targeted therapies in the management of coloRectal carcinoma: role of bevacizumab.
- Does celecoxib have a role in the treatment of patients with coloRectal cancer?
- The role of targeted therapy in the treatment of advanced coloRectal cancer.
- Carcinoembryonic antigen monitoring in metastatic coloRectal cancer: words of caution.
- Treating Rectal cancer: key issues reconsidered.
- Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of Rectal ade...
- Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time.
- Anti-EGFR monoclonal antibodies in metastatic coloRectal cancer: time for an individualized approach?
- Polyamine catabolism in coloRectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine.
- A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid Tumors.
- Neoadjuvant chemoradiation for Rectal cancer: is more better?
- Qualitative radiology assessment of tumor response: does it measure up?
- Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia.
- Significance of signet-ring cells in patients with coloRectal cancer.
- A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallBladder: a single-institution prospective study.
- 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic coloRectal cancer: a single-institute study.
- Safety and efficacy of first-line chemotherapy in unresected metastatic coloRectal cancer.
- Rectal cancer.
- Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
- Capecitabine-induced headache responding to diltiazem.
- Anti-EGFR monoclonal antibody-induced hypomagnesaemia.
- Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
- Selenium metabolites in urine of Cancer patients receiving L-selenomethionine at high doses.
- Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
- A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid Tumors.
- Toxicities and survival among octogenarians and nonagenarians with coloRectal cancer treated with chemotherapy or concurrent chemoradiation therapy.
- Idiopathic thrombocytopenic purpura in a newly diagnosed pancreatic adenoCarcinoma.
- Leukemoid reaction in pancreatic Cancer: a case report and review of the literature.
- Prevention of coloRectal cancer: an emerging role for high-dose vitamin D supplementation?
- Vitamin D compounds: clinical development as Cancer therapy and prevention agents.
- A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of Rectal adenocarcinoma.
- Cetuximab-induced hypomagnesemia in patients with coloRectal cancer.
- Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of Rectal adenocarcinoma: can we get the right dose first?
- Gemcitabine-induced rectus abdominus radiation recall.
- CEA monitoring in coloRectal cancer. What you should know.
- Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced coloRectal cancer.
- Selenium supplementation and colorectal adenomas: an Analysis of the nutritional prevention of cancer trial.
- Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced Pancreatic...
- Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia.
- A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid Tumors.
- Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic coloRectal cancer.
- Bevacizumab-induced nasal septum perforation.
- Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid Tumors.
- Selenium protects against toxicity induced by antiCancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid ...
- Anal cAnal cancer clinical practice guidelines in oncology.
- Rectal cancer clinical practice guidelines in oncology.
- Colon Cancer clinical practice guidelines in oncology.
- Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid Malignancies.
- Postoperative computed tomography scan surveillance for patients with stage II and III coloRectal cancer: worthy of further study?
- Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid Tumors.
- 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon Cancer with severe liver dysfunction.
- A report of high-dose selenium supplementation: response and toxicities.
- Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid Tumors.
- Anti-tumor activity of calcitriol: pre-clinical and clinical studies.
- First-line hepatic infusion of pirarubicin in patients with isolated Liver metastases: is it really promising?
- Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome.
- Glucocorticoids and treatment of prostate Cancer: a preclinical and clinical review.
- Unusual Tumors involving the head and neck region: case 1. Angiosarcoma of the scalp.
- Intramedullary spinal cord metastasis (ISCM) in renal cell Carcinoma: a series of six cases.
- Specific binding of Haemophilus influenzae to minor gangliosides of human respiratory epithelial cells.
Schools
American University Of Beirut
Wayne State University
University Of Pittsburgh Medical Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Bile Duct Cancer
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Internal Medicine
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
Education
-
University of Pittsburgh Medical Center -
Wayne State University School of Medicine -
American University of Beirut Faculty of Medicine
Drug Facts
| NPI NUMBER | 1861498271 | |
| NPPES Provider LastName | FAKIH | |
| NPPES Provider FirstName | MARWAN | |
| NPPES Provider ZIPCode | 910103012 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 409.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 3.67 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861498271 |
| Last Name Of The Provider | FAKIH |
| First Name Of The Provider | MARWAN |
| View All |
Similar Doctors
|
Dr. Yu Wang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Theodore G. Krontiris, MD |
|
|
Dr. Jana Portnow, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Warren Chow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamehameha K. Wong Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria F. Santander, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cathie T. Chung, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Dawn M. Gross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melanie Palomares, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Michael A. Friedman |